Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acute Myeloid Leukemia
Studies from University of Tsukuba, Medical Department provide new data on acute myeloid leukemia
April 29th, 2008
" To evaluate a less intensive chemotherapeutic regimen specifically designed for patients with Down syndrome (DS) and acute myeloid leukemia (AML), and to determine the prognostic factors for event-free survival. Patients and Methods Seventy-two patients with AML-DS were treated with remission induction chemotherapy consisting of pirarubicin (25 mg/m2/d for 2 days), cytarabine (100 mg/m2/d for 7 days), and etoposide (150 mg/m2/d for 3 days)," scientists in Tsukuba, Japan report. "Patients received four courses of intensification therapy of the same regimen. Prophylaxis for CNS leukemia was not included. All but two patients were younger than 4 years, and 67 of the 72...
Source: Cancer Weekly (2008-04-29)
|
